https://rijournals.com/research-in-medical-sciences/

RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 3(1):1-9, 2024

©RIJRMS Publications ISSN: 1597-3107

The Role of Pharmacogenomics in Personalized Medicine: Historical Context, Principles, Applications, and Future Challenges

[1]Joseph Obiezu Chukwujekwu Ezeonwumelu, [2]Uhama Kingsley Chukwuka, [3]Ugwu Okechukwu Paul-Chima, [3]Alum Esther Ugo, [4]Ugwuanyi Anthony Chukwudi and [5]Tambwe Patrick Rodrigue

[1]Department of Clinical Pharmacy and Pharmacy Practice, Kampala International University Western Campus, Uganda.
[2]Department of Biochemistry, Faculty of Applied Natural Sciences, Enugu State University of Science and Technology, Nigeria.
[3]Department of Publication and Extension Kampala International University Uganda.
[4]Department of Microbiology Ebonyi State University Abakaliki, Nigeria.
[5]Department of Public Health Kampala International University Uganda
Email: kingsley.uhama@esut.edu.ng

ABSTRACT

Pharmacogenomics, the study of how genetic variations influence drug response, plays a crucial role in the development of personalized medicine. Utilizing data from the Human Genome Project, this field aims to tailor drug therapy to individual genetic profiles, enhancing efficacy and safety. This paper explores the historical evolution, foundational principles, and clinical applications of pharmacogenomics, particularly in cancer and cardiovascular disease treatment. Additionally, it addresses the challenges and ethical considerations associated with integrating pharmacogenomic testing into clinical practice. As technological advancements continue, pharmacogenomics promises significant strides in personalized healthcare, though widespread implementation faces hurdles in regulation, cost, and public acceptance.

Keywords: Pharmacogenomics, Personalized Medicine, Genetic Variation, Drug Response, Human Genome Project, Pharmacokinetics and Pharmacodynamics

INTRODUCTION

Pharmacogenomics, a field that merges pharmacology and genomics, investigates how genetic variations affect individual responses to drugs [1]. This discipline has gained momentum with advancements from the Human Genome Project, promising to revolutionize personalized medicine by tailoring drug therapies based on genetic profiles [2]. Pharmacogenomics aims to enhance drug efficacy, minimize adverse effects, and optimize therapeutic outcomes by considering an individual's unique genetic makeup [3]. The U.S. National Institutes of Health (NIH) defines pharmacogenomics as the study of how genetic variations influence drug responses [4]. In Europe, where the Human Genome Project began, the European Medicines Agency (EMA) describes pharmacogenomics as applying genomic technologies to new pharmacological paradigms, including toxicity prediction, mechanism elucidation, target identification, and drug candidate selection [5]. This broad definition underscores the potential of pharmacogenomics to transform clinical practice by individualizing patient care. Historical evidence of genetic variation influencing drug responses dates back to the early 20th century, but only recent advancements in genotyping methods and genomic sequencing have made it feasible to integrate genetic data into clinical decision-making [6-8]. The U.S. Food and Drug Administration (FDA) emphasizes that personalized medicine involves customizing the prevention, diagnosis, and treatment of diseases based on an individual's genetic information, potentially leading to more effective and safer treatments [9-13]. This paper explores the principles and applications of pharmacogenomics, exploring how genetic variability

impacts drug response and the potential for personalized medicine [9-13]. It also addresses the historical development, current challenges, and future directions of this transformative field, highlighting the necessity for ethical considerations and regulatory frameworks to support its integration into clinical practice [14-16].

Pharmacogenomics

In addition to utilizing data from the Human Genome Project to advance the field of pharmacology, genetic information can be employed to individualize drug therapy [17-20]. Therefore, the term pharmacogenomics more adequately describes the scope and covers the potential of using human genetic variation to personalize medicine [21-24]. The U.S. National Institutes of Health defines pharmacogenomics as the study of how genetic variations affect the response to drugs [25-26]. In Europe, where the Human Genome Project commenced, the European Agency for the Evaluation of Medicinal Products defined pharmacogenomics as the application of genomic technologies to new pharmacologic paradigms [27-30]. These include toxicity prediction, mechanism elucidation, target chemical identification, and drug candidate selection [31-34]. Pharmacogenomics, a word formed by combining the terms pharmacology and genomics, can be broadly defined as the study of how genetic variations in individuals may affect drug responses [35-37]. This definition, like personalized medicine, encompasses drug properties as well as responses relating to the drug. As such, pharmacogenomics has been defined more specifically, usually based on the context of the investigation [38-40]. Personalized medicine, particularly in reference to drug pharmacokinetics and pharmacodynamics, has been a goal of pharmacologists for decades, although historical evidence that genetic variation influences drug responses dates back to the early 20th century [41-44]. Recent improvements in genotyping methods and the human genome sequence are facilitating a change in how investigators and clinicians think about the genetic contributions to drug response [45-48]. According to the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research, personalized medicine is "the science of personalizing the prevention, diagnosis, and treatment of disease based on knowledge of an individual's unique characteristics and genetic information [49-53]. It has the potential to be more effective because it is based on an understanding of the unique genetic, cellular, and environmental factors that contribute to each individual patient's conditions [54-56].

Personalized medicine

Personalized medicine happens when a disease becomes predictable and preventable based on specific genotypes. It occurs when, in cases of a disease, genetic diagnosis and the availability of prospectively validated molecular-targeted agents result in more effective and safer treatments [57-60]. Then the role of the clinician changes and shifts from trial-error assignments to rational assignments based on well-defined molecular alterations and effective drugs. The genetic revolution in terms of genomics, transcriptomics, proteomics, metabolomics, and other "-omics" has resulted in an explosion of new biological data, most of it related to individual genetic variation. As a result, today's directed personalized medicine offers unprecedented opportunities for targeting a more effective treatment of diseases such as cancer than could be achieved earlier [61]. Providing the highest-quality care based upon the best data and the most evidence-based information has always been the goal of medicine. It is now possible to achieve some elements of this in ways that have not previously been possible [50-61]. Pharmacogenomics, "pharmacogenetics," or "genomic medicine" is the study of the role of the genome in drug response. Its name (pharmaco- + genomics) reflects its combining of pharmacology and genomics. Pharmacogenomics analyzes how the genetic makeup of an individual affects his/her response to drugs. It deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with pharmacokinetics (drug absorption, distribution, metabolism, and elimination) and pharmacodynamics (effects mediated through a drug's biological targets) [40-45].

Historical Overview

The study of genetic influence on the response to drugs in persons from different ethnic backgrounds was followed by a number of reports of distinctive responses to specific drugs in characteristic population groups [4-6]. For example, enzymuria of liver isoenzyme UDP-glucuronyltransferase appears in Finnish men drinking alcohol, and methemoglobinemia after ingestion of nitrate-contaminated water is documented in the Gozitan population. At the same time as these pharmacogenetic discoveries were being made, it was found, in humans, that plasma levels of anti-nuclear antibodies differ and occur with greater frequency under certain drugs. That humoral antibody synthesis may be frustrated by drug treatment, that the elimination half-life of salicylamide correlates statistically with the polymorphonuclear white blood cell content of the individual, and that such polymorphonuclear content is connected to the incidence of isoniazid adverse reactions [8]. This was long before continuous body temperature curves could be studied during drug treatment in the human. Indeed, the validity of this test was denied in later

years, but in recent literature, it seems as if the argument is to give it a renewed chance. Despite the identification of so many human enzyme systems, few pharmacogenetic traits were known and all of those discovered were without known connections or relevance to drug therapy in human beings. An explosion of inherited enzyme variability from these primitive isozyme studies was then generated. Now, the underlying genetic mechanisms could be defined and genetic determination of polymorphic drug enzyme function could be shown [15-18]. In the first part of the 20th century, acute hemolytic reactions with primaquine and paracetamol were reported. But it was not until the 1950s that additional pharmacogenetic phenomena, such as the occurrence of peripheral neuropathy in humans due to treatment with isoniazid and suxamethonium apnoea on hydrolysis enzyme deficiency of plasma pseudocholinesterase, were uncovered. The most extensive research, which demonstrated genetic mutations as the root cause of specific drug toxicities, was conducted, however, investigating the colorectal cancer patients treated with 6-mercaptopurine and antineoplastic drugs methotrexate and 5-fluorouracil. Individual response to drug treatment depending on the ethnic origin of the patients was reported in the middle of the 20th century. It was found that patients with a certain ethnic background were prone to frequent adverse reactions from succinylcholine while another group was immune to it. Dominantly inherited tetrachromatic color vision and glucose-6-phosphate-dehydrogenase enzyme deficiency in male subjects were the first reported pharmacogenetic traits [11-17].

Principles of Pharmacogenomics

We begin by reviewing the basic principles of pharmacogenetics and genomic technologies, then present a framework that utilizes prior knowledge to analyze data from high-throughput genomic technologies to gain insight about variability in drug responses and the drug discovery process in general. Finally, we touch on the growing regulatory, commercial, and scientific infrastructure needed to bring these data into clinical use. In a sense, the promise of distilling knowledge on how the genome modulates responses to medications is being realized very rapidly through the advent of high-throughput technologies used in pharmacogenomics [11]. The field is poised to significantly benefit from wide implementation via genome-wide association studies, deep resequencing studies, and next-generation expression profiling. These approaches provide high-dimensional data, and the ability to study phenotypes in vitro in the context of the genetic immune response makes them ideal for pharmacogenomic studies [14]. Pharmacogenomics is the study of individual genetic differences in the potential response to medication. The field incorporates a variety of genetic and expression data, including the study of inheritable variations in the human genome that influence a patient's response to drug therapy. We believe that using pharmacogenomics will allow us to discover new knowledge on the effectiveness of current drug treatments, to take advantage of existing gene expression profiling, to enhance drug development, to optimize drug therapy, and to prevent adverse events, ultimately providing the rationale for using targeted preventive and therapeutic strategies [8].

Genetic Variability and Drug Response

Individuals respond differently to drugs. In regard to these differences, there is potential to explore a person's genetic constitution. These constitutions can then serve as markers of an individual's sensitivity to a specific drug or adverse reaction. Individuals have been shown to metabolize drugs shortly, minimizing the capability of the reactive toxic agent. Genetic variability and drug response are important issues for patient care [11-16]. Factors determine drug efficacy and how it should be administered at the lowest possible dose for the shortest amount of time. This information is significant in order to adjust drug therapy for special patient groups. By considering individual components of drug-metabolizing enzymes or drug targets, one can predict the likelihood of therapeutic success. Variability associated with a single nucleotide polymorphism in a group of persons can help predict the development of disease, thus influencing the prophylactic use of drugs in individuals designated as high risk based on genotype [9].

Pharmacokinetics and Pharmacodynamics

The field of pharmacogenomics has now expanded and includes genetic variation, such as single nucleotide polymorphisms, copy number variations, insertions, and deletions, gene duplications, gene deletions, small insertions and deletions, aberrations in RNA expression, and other variations in the human genome. Genetic differences in the proteins involved in the absorption, distribution, metabolism, and excretion of a drug can influence the extent and duration of drug exposure to its active or inactive metabolites. The five core pharmacokinetic processes are absorption, distribution, metabolism, elimination, and excretion. An alteration in one or more of these core processes as a result of a genetic mutation can lead to altered drug concentration, thereby influencing the treatment outcome [11-17]. The basic approach of personalized medicine is to use individual traits to devise optimal treatment regimens. This implies treating an individual as a special instance of a certain type and identifying the characteristics of this individual that make him or her distinct from the rest. The cornerstone of

personalized medicine is the adherence to the concept of individuality and the recognition that each patient is unique. This uniqueness arises due to genetic variations in their genome. Variation in genomic DNA has an impact on the pharmacokinetic and pharmacodynamic properties of a drug. Variability in the pharmacokinetics and pharmacodynamics of a drug accounts for the inter-individual variations seen in drug response. The term "pharmacogenetic" concerns specifically with these inherited differences in the blood concentration for a defined dose of drug [21-25].

Applications of Pharmacogenomics

Pharmacogenomics research has the potential to lead to the identification of hundreds of new drug targets, thus accelerating drug discovery. A more reliable prediction of which compounds will cause toxic effects in humans could be enabled using the newly emerging functional-genomics profiling tools. Additionally, therapy optimization for existing drugs could reduce the bloat and duration of expensive drug development programs as patients who are less likely to benefit from drug therapy could be identified earlier, confounding effects on clinical trials could be minimized and sample sizes reduced and, potentially costly and environmentally hazardous post-marketing drug withdrawal may be avoided. It could also aid the development of safer drugs as compounds that lead to adverse events will be eliminated earlier in the drug peer review process [11-14]. Over the past decade, interest has grown in the clinical application of pharmacogenomics in drug therapy. Pharmacogenomics has been proposed as a way to personalize therapy based on the unique characteristics of each patient. The technology of pharmacogenomics promises a future in which drug therapy can be tailored to fit each person's genetic make-up. Pharmacogenomics also holds out the possibility that the personal genome sequence will become a major source of predictive medical knowledge. Individuals could be pre-screened for susceptibility to both genetically complex disorders and adverse drug reactions before any symptoms appear. This individualized prediction might allow for personalized disease prevention and early treatment while the disease is still at its most manageable stage. In addition to pre-screening of adults, preimplantation genetic diagnosis of embryos could allow at-risk mutations and gamete selection to prevent inheritance of the conditions by future generations [10-16].

Cancer Treatment

Karger has published a monograph 'Pharmacogenomics of Human Drug Transporters' (2008). The issue is very important because drug transporters are needed to accumulate in cancer cells chemotherapeutics. It is known that multidrug resistance often leads to the low therapy efficacy. Classification of human transporters (ATP binding cassettes, SLCO, SLC22A, SLC28A, SLC29A, SLC15A, SLC16A, and LR RC (Cystic Fibrosis Transmembrane Conductance Regulator)) and their role in the responsiveness of cancer patients to chemotherapy are presented in the monograph. Karger has published a monograph 'Pharmacogenomics of Human Drug Transporters' [40-46]. The issue is very important because drug transporters are needed to accumulate in cancer cells chemotherapeutics. It is known that multidrug resistance often leads to the low therapy efficacy. Classification of human transporters (ATP binding cassettes, SLCO, SLC22A, SLC28A, SLC29A, SLC15A, SLC16A, and LR RC (Cystic Fibrosis Transmembrane Conductance Regulator)) and their role in the responsiveness of cancer patients to chemotherapy are presented in the monograph [30-34]. Recent results of pharmacogenomics investigations in oncology revealed promising possibilities to define the putative non-responders to conventional chemotherapy of solid tumors. Expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, thymidine phosphorylase, thymidine phosphorylase (platelet-derived endothelial cell growth factor), cyclin E and securin, UGT1A (encode for uridine diphosphate-glucuronosyl transferase), and topoisomerase I predict the patients that are likely to be non-responders to 5-fluorouracil, capecitabine, camptoetericins or irinotecan therapy. Moreover, expression profiles of a number of genes are able to evaluate the therapeutic efficacy and disease progression of the patients suffering from tumors resistant to the drugs [7-13].

Cardiovascular Diseases

Cardiovascular diseases are the leading cause of death in both developed and developing economies. An overall improvement of public healthcare and an increase in the standard of living have caused a 60% reduction of the mortality rate associated with cardiovascular diseases in developed countries. However, a trend of life expectancy that continues to increase is combined with an increase in the number of people who have to come to terms with cardiovascular diseases [17-23]. This is particularly true in developed economies, among particular communities, marginalized people, and older people. It is estimated that in thirty years' time, CAGD will be the cause of 40% of all deaths worldwide. With an increase in the number of people who have had a heart attack and those who suffer from chronic ischemic heart disease, this is increasingly becoming a serious public health concern. The efficacy of the treatment of cardiovascular diseases depends on the way an individual organism responds to the administered drugs.

Such responses are also often characterized by high toxicity. With the objective of finding the genetic determinative factors of the individual response to the treatment and the determination of these responses, a number of genetic studies have been conducted. The results of these studies have either been completely confirmed or are in the process of confirmation. An additional study of the individual variants and the possible ways in which these variants affect the response to treatment are essential genetic research in the field of pharmacogenomics [31-36].

Challenges and Future Directions

The most important challenges for the field stem from the multifactorial nature of most clinically important phenotypes. Diverse genetic and acquired factors may contribute to observed inter-individual differences in treatment response. Furthermore, some genetic factors may determine differences in susceptibility to drug-related adverse events, which can lead to morbidity and mortality. There are also many barriers to the implementation of personalized medicine strategies. Some of the most important concerns include medical inertia, acceptance of evidence derived from genetic studies, regulatory requirements, conflicts of interest, and prioritization of rare versus common disease by regulatory agencies [31-36]. The success of pharmacogenomic research has underscored the importance of personalizing medicine for each individual. Although much excitement has surrounded the potential benefits of this research, numerous challenges must be addressed in order to translate pharmacogenomic discoveries into clinical practice. The clinical use of pharmacogenomic tests requires that reliable genetic tests be developed and available for clinical use in the identification of which patients will benefit from medication. There is currently considerable variability in the performance and clinical availability of many of these tests, including variation in turnaround time and cost. Furthermore, there may be a perception that large-scale adoption of expensive genetic testing may result in cost shifting and prohibitive impacts on healthcare costs [37-43].

Ethical and Legal Issues

These principles, as much as possible, should conform to data protection directives and regulations at the national and international levels. At the national level, patient consents remain essential components of pharmacogenomic protocols. Patients should be able to give consent for particular types of pharmacogenomic research and the use of their samples. In the case of minors, institutional review boards and established guardians should decide on their behalf [44-47]. The question of whether pharmacogenomic research should be permitted without explicit consent remains. This is a particularly difficult problem to manage in developing countries where regulation of genetic research is not yet developed. The development and application of pharmacogenomics and personalized medicine technologies provide several ethical, social, and legal challenges in terms of improving and maintaining the level of public health. Some of these challenges are as follows: The Hamamatsu World Conference on Comprehensive Personalized Medicine made a recommendation for the development and implementation of guiding principles on privacy and access to information that is derived from any personal genetic information collected as part of the patient's medical record. Pharmacogenomic information could reveal a patient's predisposition to (future) diseases. Moreover, treatment regulations could create a system of unequal access to healthcare, particularly concerning an individual's rights to access genetic and health records [48-49].

Integration into Clinical Practice

Several groups have already developed guidelines on the use of pharmacogenomic tests. Prompted by the fact that CYP2D6 genotyping is already beginning to influence clinical practice, a panel of experts recently published clinical guidelines for the use of CYP2D6 and CYP2C19 genotyping. This panel recommended that patients be genotyped for CYP2D6 and CYP2C19 if they are candidates for treatment with tricyclic antidepressants, amitriptyline, nortriptyline, desipramine, imipramine, clomipramine, antipsychotics, risperidone, or phenothiazines, first generation antipsychotics, haloperidol, perphenzine, thioridazine, fluphenazine, loxapine, thiothixene. Among the guidelines is the recommendation that "levomepromazine, haloperidol, perphenzine, or other low therapeutic index antipsychotic agents should generally be avoided in patients identified as CYP2D6 or CYP2C19 poor metabolizer." Pharmacogenomics is currently not an integral part of clinical practice. There are, however, several areas of pharmacogenomic testing that have successfully transitioned to the clinical realm. Generally, these are tests where the implementation cost is low, the risk of adverse outcomes is high, and avoidance of the adverse outcome relies on only one or two available therapeutic alternatives [33-36].

CONCLUSION

Pharmacogenomics represents a transformative approach to drug therapy, leveraging genetic information to personalize medical treatment. The historical context highlights the significant progress made from early 20th-century discoveries to the present-day application of genomic technologies. Principles such as

genetic variability and its impact on pharmacokinetics and pharmacodynamics underscore the importance of individualized therapy. Clinical applications, particularly in oncology and cardiovascular diseases, demonstrate the potential for improved therapeutic outcomes and reduced adverse effects. However, several challenges remain. Ethical and legal issues, such as patient consent and data privacy, must be carefully navigated. Additionally, the integration of pharmacogenomics into routine clinical practice requires overcoming barriers related to cost, regulatory approval, and healthcare infrastructure. Future research and policy development will be crucial in addressing these obstacles and realizing the full potential of pharmacogenomics. In conclusion, while the journey towards fully personalized medicine is ongoing, pharmacogenomics offers a promising pathway to more effective and safer treatments, fundamentally altering the landscape of healthcare.

REFERENCES

1. Malsagova, K. A., Butkova, T. V., Kopylov, A. T., Izotov, A. A., Potoldykova, N. V., Enikeev, D. V., ... & Kaysheva, A. L. (2020). Pharmacogenetic testing: a tool for personalized drug therapy optimization. Pharmaceutics, 12(12), 1240. mdpi.com
2. Singh, D. B. (2020). The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology. ethernet.edu.et
3. Cecchin, E. & Stocco, G. (2020). Pharmacogenomics and personalized medicine. Genes. mdpi.com
4. Micaglio, E., Locati, E. T., Monasky, M. M., Romani, F., Heilbron, F., & Pappone, C. (2021). Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine. Frontiers in pharmacology, 12, 651720. frontiersin.org
5. Carr, D. F. & Turner…, R. M. (2021). Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical …. wiley.com
6. Primorac, D., Bach-Rojecky, L., Vađunec, D., Juginović, A., Žunić, K., Matišić, V., ... & Donaldson, M. (2020). Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. Pharmacogenomics, 21(2), 141-156. futuremedicine.com
7. Duarte, J. D. & Cavallari, L. H. (2021). Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology. nih.gov
8. Hassan, R., Allali, I., Agamah, F. E., Elsheikh, S. S., Thomford, N. E., Dandara, C., & Chimusa, E. R. (2021). Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. Briefings in bioinformatics, 22(4), bbaa292. researchgate.net
9. Pirmohamed, M. (2023). Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics. units.it
10. van der Lee, M., Kriek, M., Guchelaar, H. J., & Swen, J. J. (2020). Technologies for pharmacogenomics: a review. Genes. mdpi.com
11. Feng, F., Shen, B., Mou, X., Li, Y., & Li, H. (2021). Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. Journal of Genetics and Genomics. sciencedirect.com
12. Malki, M. A. & Pearson, E. R. (2020). Drug–drug–gene interactions and adverse drug reactions. The pharmacogenomics journal. nature.com
13. Adam, G., Rampášek, L., Safikhani, Z., Smirnov, P., Haibe-Kains, B., & Goldenberg, A. (2020). Machine learning approaches to drug response prediction: challenges and recent progress. NPJ precision oncology, 4(1), 19. nature.com
14. Choudhary, S., Sreenivasulu, K., Mitra, P., Misra, S., & Sharma, P. (2021). Role of genetic variants and gene expression in the susceptibility and severity of COVID-19. Annals of laboratory medicine, 41(2), 129. nih.gov
15. Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., ... & Kloczkowski, A. (2022). Innovations in genomics and big data analytics for personalized medicine and health care: A review. International journal of molecular Sciences, 23(9), 4645. mdpi.com
16. Raparthi, M. (2020). Deep Learning for Personalized Medicine-Enhancing Precision Health With AI. Journal of Science & Technology. thesciencebrigade.com
17. Singh, A. V., Chandrasekar, V., Paudel, N., Laux, P., Luch, A., Gemmati, D., ... & Dakua, S. P. (2023). Integrative toxicogenomics: Advancing precision medicine and toxicology through artificial intelligence and OMICs technology. Biomedicine & Pharmacotherapy, 163, 114784. sciencedirect.com

18. Raparthi, M. (2022). AI Assisted Drug Discovery: Emphasizing Its Role in Accelerating Precision Medicine Initiatives and Improving Treatment Outcomes. Human-Computer Interaction Perspectives. thesciencebrigade.com
19. Helbig, I. & Ellis, C. A. (2020). Personalized medicine in genetic epilepsies–possibilities, challenges, and new frontiers. Neuropharmacology. [HTML]
20. Strianese, O., Rizzo, F., Ciccarelli, M., Galasso, G., D'Agostino, Y., Salvati, A., ... & Rusciano, M. R. (2020). Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes, 11(7), 747. mdpi.com
21. Infante, T., Del Viscovo, L., De Rimini, M. L., Padula, S., Caso, P., & Napoli, C. (2020). Network medicine: a clinical approach for precision medicine and personalized therapy in coronary heart disease. Journal of Atherosclerosis and Thrombosis, 27(4), 279-302. jst.go.jp
22. Connaughton, D. M., & Hildebrandt, F. (2020). Personalized medicine in chronic kidney disease by detection of monogenic mutations. Nephrology Dialysis Transplantation, 35(3), 390-397. nih.gov
23. Kölker, S., Gleich, F., Mütze, U., & Opladen, T. (2022). Rare disease registries are key to evidence-based personalized medicine: highlighting the European experience. Frontiers in Endocrinology. frontiersin.org
24. Ray, D. K., Kohar, D., Nepal, R., Sharma, P., Kajal, V., Singh, Y., & Phogat, J. (2023). Unraveling the genetic Code: Pharmacogenomics' Role in personalized Drug Responses. Journal of Pharma Insights and Research, 1(2), 015-020. jopir.in
25. Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., ... & Wherry, E. J. (2020). Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science, 369(6508), eabc8511. science.org
26. Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020). Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ breast cancer, 6(1), 54. nature.com
27. Ramón y Cajal, S., Sesé, M., Capdevila, C., Aasen, T., De Mattos-Arruda, L., Diaz-Cano, S. J., ... & Castellví, J. (2020). Clinical implications of intratumor heterogeneity: challenges and opportunities. Journal of Molecular Medicine, 98, 161-177. springer.com
28. Kariuki, J. G., Kariuki, S. M., & Angel, P. (2023). … Pyridoxine in the Prevention and Treatment of Neuropathy and Neurotoxicity Associated with Rifampicin-Resistant Tuberculosis Treatment Regimens: A Topic …. Journal of Tuberculosis Research. scirp.org
29. Jones, M. R., Urits, I., Wolf, J., Corrigan, D., Colburn, L., Peterson, E., ... & Viswanath, O. (2020). Drug-induced peripheral neuropathy: a narrative review. Current Clinical Pharmacology, 15(1), 38-48. nih.gov
30. Shetty, P., Panchal, F., Munshi, R., Sundar, U., & Darole, P. (2020). A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India. Indian Journal of Tuberculosis, 67(3), 407-410. [HTML]
31. Tong, H., Phan, N. V., Nguyen, T. T., Nguyen, D. V., Vo, N. S., & Le, L. (2021). Review on databases and bioinformatic approaches on pharmacogenomics of adverse drug reactions. Pharmacogenomics and Personalized Medicine, 61-75. tandfonline.com
32. Bature, J. T., Eruaga, M. A., & Itua, E. O. (2024). Integrating pharmacogenomic testing into personalized medicine practices in the USA: Implications for medication quality control and therapeutic efficacy. GSC Biological and Pharmaceutical Sciences, 26(3), 019-026. gsconlinepress.com
33. Ahmed, Z., Zeeshan, S., Mendhe, D., & Dong, X. (2020). Human gene and disease associations for clinical-genomics and precision medicine research. Clinical and translational medicine, 10(1), 297-318. wiley.com
34. Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., ... & Hassan, M. M. (2022). Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Frontiers in Oncology, 12, 891652. frontiersin.org
35. Berman, J. & Krysan, D. J. (2020). Drug resistance and tolerance in fungi. Nature Reviews Microbiology. nih.gov
36. Vinarov, Z., Abdallah, M., Agundez, J. A., Allegaert, K., Basit, A. W., Braeckmans, M., ... & Augustijns, P. (2021). Impact of gastrointestinal tract variability on oral drug absorption and

pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 162, 105812. sciencedirect.com

37. Pereira, L., Mutesa, L., Tindana, P., & Ramsay, M. (2021). African genetic diversity and adaptation inform a precision medicine agenda. Nature Reviews Genetics. [HTML]
38. Wei, C. Y., Yang, J. H., Yeh, E. C., Tsai, M. F., Kao, H. J., Lo, C. Z., ... & Kwok, P. Y. (2021). Genetic profiles of 103,106 individuals in the Taiwan Biobank provide insights into the health and history of Han Chinese. NPJ genomic medicine, 6(1), 10. nature.com
39. Auwerx, C., Sadler, M. C., Reymond, A., & Kutalik, Z. (2022). From pharmacogenetics to pharmaco-omics: Milestones and future directions. Human Genetics and Genomics Advances, 3(2). cell.com
40. Arbitrio, M., Scionti, F., Di Martino, M. T., Caracciolo, D., Pensabene, L., Tassone, P., & Tagliaferri, P. (2021). Pharmacogenomics biomarker discovery and validation for translation in clinical practice. Clinical and Translational Science, 14(1), 113-119. wiley.com
41. Kawasaki, Y., Kakimoto, K., Tanaka, Y., Shimizu, H., Nishida, K., Numa, K., ... & Nishikawa, H. (2023). Relationship between Chemotherapy-Induced Diarrhea and Intestinal Microbiome Composition. Digestion, 104(5), 357-369. karger.com
42. Salvatorelli, E., Minotti, G., & Menna, P. (2023). New Targeted Drugs for Acute Myeloid Leukemia and Antifungals: Pharmacokinetic Challenges and Opportunities. Chemotherapy. researchgate.net
43. Cho, C. H. & Hu, T. (2020). Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies. [HTML]
44. Li, Y., Liu, J., Cai, X. W., Li, H. X., Cheng, Y., Dong, X. H., ... & Fu, X. L. (2021). Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review. Critical Reviews in Oncology/Hematology, 167, 103466. [HTML]
45. Koulis, C., Yap, R., Engel, R., Jardé, T., Wilkins, S., Solon, G., ... & McMurrick, P. (2020). Personalized medicine—current and emerging predictive and prognostic biomarkers in colorectal cancer. Cancers, 12(4), 812. mdpi.com
46. Yamada, Y. (2022). Present status and perspective of perioperative chemotherapy for patients with resectable pancreatic cancer in Japan. Global Health & Medicine. jst.go.jp
47. Pavlíková, L., Šereš, M., Breier, A., & Sulová, Z. (2022). The Roles of microRNAs in Cancer Multidrug Resistance. Cancers 2022, 14, 1090. researchgate.net
48. Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022). The global burden of cardiovascular diseases and risk: a compass for future health. Journal of the American College of Cardiology, 80(25), 2361-2371. jacc.org
49. Timmis, A., Townsend, N., Gale, C. P., Torbica, A., Lettino, M., Petersen, S. E., ... & Vardas, P. (2020). European Society of Cardiology: cardiovascular disease statistics 2019. European heart journal, 41(1), 12-85. uliege.be
50. Li, Z., Lin, L., Wu, H., Yan, L., Wang, H., Yang, H., & Li, H. (2021). Global, regional, and national death, and disability-adjusted life-years (DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the global burden of disease study and implications for prevention. Frontiers in public health, 9, 559751. frontiersin.org
51. Yang, S. C., Chen, C. B., Lin, M. Y., Zhang, Z. Y., Jia, X. Y., Huang, M., ... & Chung, W. H. (2021). Genetics of severe cutaneous adverse reactions. Frontiers in Medicine, 8, 652091. frontiersin.org
52. Matthee, C., Brown, A. R., Lange, A., & Tyler, C. R. (2023). Factors determining the susceptibility of fish to effects of human pharmaceuticals. Environmental science & technology, 57(24), 8845-8862. acs.org
53. Nagy, M., Eirini Tsermpini, E., Siamoglou, S., & Patrinos, G. P. (2020). Evaluating the current level of pharmacists' pharmacogenomics knowledge and its impact on pharmacogenomics implementation. Pharmacogenomics, 21(16), 1179-1189. [HTML]
54. Allen, J. D., Pittenger, A. L., & Bishop, J. R. (2022). A scoping review of attitudes and experiences with pharmacogenomic testing among patients and the general public: implications for patient counseling. Journal of Personalized Medicine. mdpi.com
55. Hayward, J., McDermott, J., Qureshi, N., & Newman, W. (2021). Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models. Pharmacogenomics, 22(12), 761-776. futuremedicine.com

56. Turner, R. M., Newman, W. G., Bramon, E., McNamee, C. J., Wong, W. L., Misbah, S., ... & Pirmohamed, M. (2020). Pharmacogenomics in the UK National Health Service: opportunities and challenges. Pharmacogenomics, 21(17), 1237-1246. ucl.ac.uk
57. Pratt, V. M., Cavallari, L. H., Del Tredici, A. L., Gaedigk, A., Hachad, H., Ji, Y., ... & Weck, K. E. (2021). Recommendations for clinical CYP2D6 genotyping allele selection: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch pharmacogenetics working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. The Journal of Molecular Diagnostics, 23(9), 1047-1064. sciencedirect.com
58. Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., ... & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51-68. cpicpgx.org
59. Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., ... & Gaedigk, A. (2020). Standardizing CYP 2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and translational science, 13(1), 116-124. wiley.com
60. Milosavljević, F., Bukvić, N., Pavlović, Z., Miljević, Č., Pešić, V., Molden, E., ... & Jukić, M. M. (2021). Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA psychiatry, 78(3), 270-280. jamanetwork.com
61. Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020). A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes, 11(11), 1295. mdpi.com

CITE AS: Joseph Obiezu Chukwujekwu Ezeonwumelu, Uhama Kingsley Chukwuka, Ugwu Okechukwu Paul-Chima, Alum Esther Ugo, Ugwuanyi Anthony Chukwudi and Tambwe Patrick Rodrigue (2024). The Role of Pharmacogenomics in Personalized Medicine: Historical Context, Principles, Applications, and Future Challenges. RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 3(1):1-9.